CAL-101 with bortezomib triggers synergistic cytotoxicity
| . | Bortezomib (nM) . | CAL-101 (μM) . | Fa . | CI . |
|---|---|---|---|---|
| LB | ||||
| 2.5 | 1.25 | 0.39 | 0.57 | |
| 2.5 | 2.5 | 0.52 | 0.58 | |
| 2.5 | 5 | 0.57 | 0.67 | |
| 5 | 1.25 | 0.42 | 0.88 | |
| 5 | 2.5 | 0.60 | 0.25 | |
| 5 | 5 | 0.67 | 0.22 | |
| INA-6 | ||||
| 2.5 | 1.25 | 0.49 | 0.31 | |
| 2.5 | 2.5 | 0.58 | 0.48 | |
| 2.5 | 5 | 0.69 | 0.54 | |
| 5 | 1.25 | 0.56 | 0.73 | |
| 5 | 2.5 | 0.66 | 0.42 | |
| 5 | 5 | 0.75 | 0.31 |
| . | Bortezomib (nM) . | CAL-101 (μM) . | Fa . | CI . |
|---|---|---|---|---|
| LB | ||||
| 2.5 | 1.25 | 0.39 | 0.57 | |
| 2.5 | 2.5 | 0.52 | 0.58 | |
| 2.5 | 5 | 0.57 | 0.67 | |
| 5 | 1.25 | 0.42 | 0.88 | |
| 5 | 2.5 | 0.60 | 0.25 | |
| 5 | 5 | 0.67 | 0.22 | |
| INA-6 | ||||
| 2.5 | 1.25 | 0.49 | 0.31 | |
| 2.5 | 2.5 | 0.58 | 0.48 | |
| 2.5 | 5 | 0.69 | 0.54 | |
| 5 | 1.25 | 0.56 | 0.73 | |
| 5 | 2.5 | 0.66 | 0.42 | |
| 5 | 5 | 0.75 | 0.31 |
LB and INA-6 cells were treated with bortezomib (2.5-5nM) and/or CAL-101 (1.25-5.0μM). Cytotoxicity was assessed by MTT assay. CI indicates combination index; and Fa, affected fraction. All doses show CI < 1.